Company intelligence / Profile preview

AsymBio

Shanghai, Shanghai, Chinaasymbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

No direct clinical results since it is a service provider/CDMO. Provides comprehensive capabilities from process development through commercial manufacturing across multiple modalities including mAbs, ADCs, plasmids, and mRNAs. Recognized for high-quality services with global reach and innovative technology platforms under continuous optimization.

Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Recombinant biotherapeuticsBioconjugatesPlasmidsmRNA/LNPs
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on AsymBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AsymBio.

Explore the full profile